BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s lead drug candidate bezisterim inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer’s and Parkinson’s. Bezisterim is also being evaluated to treat the neurological symptoms associated with long COVID, which are associated with persistent systematic inflammation and neuroinflammation. In liver disease, the Company is actively exploring partnerships for a Phase 3 trial to evaluate BIV201 (continuous infusion terlipressin) to reduce further decompensation in participants with liver cirrhosis and ascites. BIV201 has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months.